Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Hetero Research Foundation develops antiviral agents

Oct. 3, 2016

Phase IIb trial of Genocea's GEN-003 achieves primary endpoint

Sep. 30, 2016

Arbutus Biopharma reports interim results from phase II trial of ARB-1467 in chronic HBV

Sep. 30, 2016

Redx compounds effective against drug-resistant strains of Gram-negative bacteria

Sep. 28, 2016

Emory University discloses RNA-directed RNA polymerase inhibitors

Sep. 27, 2016

Vical starts phase II trial of VCL-HB01 in HSV-2 infection

Sep. 27, 2016

FDA grants fast track designation to PfSPZ vaccine

Sep. 23, 2016

Phase IIb results for the GMZ-2 malaria vaccine in African children

Sep. 23, 2016

The Medicines Company enters strategic partnership with BARDA to develop new antibiotics

Sep. 23, 2016

Cidara Therapeutics selects candidate from immunotherapy discovery platform

Sep. 23, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld Science
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.